Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia
Conditions
Interventions
Plasminogen (Human) intravenous
Locations
2
United States
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana, United States
Oslo University Hospital HF
Oslo, Sognsvannvejen 20, Norway
Start Date
May 4, 2016
Primary Completion Date
December 17, 2017
Completion Date
October 8, 2018
Last Updated
August 2, 2021
Lead Sponsor
Prometic Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions